Seattle Genetics, Inc.

NASDAQ: SGEN
$196.92
-$3.74 (-1.9%)
Closing price October 23, 2020
Tuesday’s top analyst upgrades and downgrades included Alibaba, Amazon.com, Apple, Carvana, Illumina, NextEra Energy, Nikola, Shake Shack, Teladoc Health and WPX Energy.
Tuesday's top analyst upgrades and downgrades included Alphabet, Citigroup, Facebook, Lennar, Netflix, NextEra, Nvidia, Nike, Pinterest, Roku and Snap.
Friday's top analyst upgrades and downgrades included Alexion Pharmaceuticals, Allscripts Healthcare Solutions, Alphabet, Amazon.com, Apple, Baidu, Comcast, Electronic Arts, Ford and Facebook.
We screened the Goldman Sachs Conviction List for the stocks that have the biggest upside to the firm's price targets and found five that look like outstanding ideas for the balance of 2020 and...
Goldman Sachs has seven biopharma stocks on its Conviction Buy list, and these are not all coronavirus plays. The firm thinks these stocks could go on the offensive for the rest of the year.
Friday's top analyst upgrades and downgrades included AGNC Investment, Annaly Capital Management, Arbutus Biopharma, Blackstone, Chevron, Enphase Energy, Exxon Mobil, General Motors, Intel, Tesla and...
Tuesday's top analyst upgrades and downgrades included ANGI Homeservices, Carnival, Chegg, Clorox, Crocs, Dish Network, Etsy, Intercept Pharmaceuticals, Micron Technology, Okta, Seattle Genetics,...
Goldman Sachs analysts are bullish on these four top biotech stocks in front of first-quarter results. None of these companies is a proverbial one-trick pony, and they all are potential takeover...
Tuesday's top analyst upgrades, downgrades and initiations included AbbVie, Apple, Arconic, CenturyLink, eHealth, Nvidia, Salesforce.com, Tesla and Teva Pharmaceutical.
Top analyst upgrades, downgrades and initiations for the first trading day of 2020 included Abbott Laboratories, Advanced Micro Devices, Analog Devices, Applied Materials, Ford, Illumina, Medtronic,...
Seattle Genetics shares jumped on Monday after the firm announced positive results from its midstage breast cancer trial.
Tuesday's top analyst upgrades, downgrades and initiations included Analog Devices, Blackstone, Bloom Energy, Cleveland-Cliffs, Ford, Micron Technology, PG&E, Snap and VMWare.
Immunomedics shares dropped sharply on Monday after the firm presented interim data from its midstage bladder cancer study at the European Society for Medical Oncology (ESMO) Annual Congress in...
Friday's top analyst upgrades, downgrades and initiations included Box, iRobot, Kimberly-Clark, Match, Oracle, Pinterest, Seattle Genetics andTexas Instruments.
24/7 Wall St. has looked over some of the biotech sector's laggards, and we have also looked over the top exchange-traded funds for a breakdown of what they own to show how much they are lagging...